RenovoRx (RNXT) risk factors, FY2024 10-K

Other

1. 01Our estimates of total addressable market, potential revenues and similar metrics related to our commercialization efforts for RenovoCath may prove inaccurate, particularly given that our commercialization efforts are relatively new and are evolving
2. 02Our revenues and results of operations may be difficult to predict and may fluctuate from quarter to quarter, which could adversely affect our business and the market price of our common stock
3. 03As our ongoing TIGeR-PaC study is our most advanced clinical trial to date, the failure of the study to achieve results conducive to progressing the study or filing and receiving NDA approval would cause our company significant harm
4. 04The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our investors

Risks Related to Our Business, Financial Condition and Capital Requirements

1. 05Alongside our Phase III clinical activities related to IAG, in 2024 we commenced efforts to commercialize our FDA-approved RenovoCath device on a standalone basis. Our commercialization efforts for RenovoCath are relatively new and evolving and we presently have very little operating experience in this business model
2. 06These factors make any assessment of our future success and viability subject to significant uncertainty. As a result, it may be more difficult for investors to accurately predict our likelihood of success and viability than it could be if we had a more mature operating history
3. 07We have incurred significant net losses in each period since inception, and we expect to continue to incur net losses until we receive FDA approval for our product candidate or until our commercial strategy for RenovoCath generates sufficient revenues
4. 08We are executing on a commercial strategy for selling our RenovoCath device on a standalone basis, which is a new activity for our company and subject to significant inherent risks
5. 09Due to all of the foregoing factors, in some future quarters our operating results may fall below the expectations of securities analysts and investors. In such event, the market price of our common stock would likely decrease
6. 10We may consider strategic alternatives in order to maximize stockholder value, including financing, strategic alliances, and licensing arrangements. We may not be able to identify or consummate any suitable strategic alternatives and any consummated strategic alternatives may not be successful

Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates

1. 11As our ongoing TIGeR-PaC study is our most advanced clinical trial to date, the failure of the study to achieve results conducive to progressing the study or filing and receiving NDA approval would cause our company significant harm
2. 12If we do not achieve our projected development goals in the timeframes we announce and expect, our stock price may decline
3. 13Our product candidates may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products or investigational new drugs, which may delay or preclude further development or regulatory approval or limit their use if approved
4. 14Interim, preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
5. 15We have limited capacity for recruiting and managing clinical trials, which could impair our timing to initiate or complete clinical trials of our product candidate and materially harm our business
6. 16We, and our collaborators, if any, must comply with extensive government regulations in order to advance our product candidates through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad
7. 17Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results
8. 18Delays in clinical testing and formulating the results of such test could result in increased costs to us and delay our ability to obtained necessary regulatory approves and generate revenue
9. 19The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed
10. 20This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations, prospects and our underlying stock price
11. 21We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates
12. 22If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected
13. 23If we are unable to satisfy regulatory requirements, we may not be able to commercialize our product candidates
14. 24If our product candidates are unable to compete effectively with marketed drugs targeting similar indications as our product candidates, our commercial opportunity will be reduced or eliminated
15. 25If the manufacturers upon whom we rely fail to produce our product candidates, in the volumes that we require on a timely basis or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidates
16. 26We may not be able to manufacture our product candidates in commercial quantities, which would prevent us from commercializing our product candidates
17. 27Our product candidates, if approved for sale, may not gain acceptance among physicians, patients, and the medical community, thereby limiting our potential to generate revenues
18. 28Guidelines and recommendations published by various organizations can impact the use of our products
19. 29The market for our lead drug/device combination product and our other product candidates may not be as large as we expect
20. 30In the event that we need to change our third-party contract manufacturers, our preclinical studies, clinical trials or the commercialization of our product candidates or FDA-approved products could be delayed, adversely affected or terminated, or such a change may result in significantly higher costs
21. 31We currently do not have any internal drug discovery capabilities, and therefore we are dependent on identifying drugs that are off patent or on in-licensing or acquiring development programs from third parties in order to obtain additional product candidates
22. 32If a product liability claim is successfully brought against us for uninsured liabilities, or such a claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business
23. 33We may delay or terminate the development of our product candidates at any time if we believe the perceived market or commercial opportunity does not justify further investment, which could materially harm our business

Risks Related to Our Operations

1. 34Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
2. 35We will need to increase the size of our organization, and we may experience difficulties in managing growth
3. 36Business disruptions could seriously harm future revenue and financial condition and increase our costs and expenses
4. 37Catastrophic events and man-made problems, such as terrorism, war, or climate change may disrupt our business
5. 38Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business
6. 39We and our third-party contract manufacturers must comply with environmental, health and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant costs or liabilities
7. 40A variety of risks associated with operating internationally could materially adversely affect our business
8. 41General economic or business conditions may have a negative impact on our business
9. 42Our operations are subject to the effects of a rising rate of inflation
10. 43Healthcare reform measures could adversely affect our business. The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown and may adversely affect our business model
11. 44Reimbursement for any approved products may be limited or unavailable, which could make it difficult for us to sell our product candidates profitably
12. 45Adverse pricing limitations may hinder our ability to recoup our investment in our existing and any future product candidates, even if such product candidates obtain marketing approval
13. 46Any legal proceedings or claims against us could be costly and time-consuming to defend and could harm our reputation regardless of the outcome
14. 47Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition
15. 48Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations

Risks Related to Intellectual Property

1. 49If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage
2. 50If any of our patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively
3. 51If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
4. 52The patents issued to us may not be broad enough to provide any meaningful protection, one or more of our competitors may develop more effective technologies, designs or methods without infringing our intellectual property rights and one or more of our competitors may design around our proprietary technologies
5. 53We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights
6. 54Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 55If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed

Risks Related to Our Common Stock

1. 56An active trading market for our common stock may not be sustained
2. 57The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for investors
3. 58Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us
4. 59Our common stock is listed on the Nasdaq Capital Market. In order to maintain our listing, we must meet minimum financial and other requirements, including a minimum amount in stockholders’ equity
5. 60We could be subject to securities class action litigation
6. 61If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline
7. 62We do not expect to pay dividends in the foreseeable future, and you must rely on price appreciation of your shares for return on your investment
8. 63We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to devote substantial time to new compliance initiatives and corporate governance practices
9. 64Pursuant to Section 404 of SOX (“Section 404”), we are required to furnish a report by our senior management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form 10-K with the SEC
10. 65Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
11. 66We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors
12. 67Anti-takeover and other provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt and have other impacts on our corporate governance
13. 68The exclusive forum provision is limited to the extent permitted by law, and it will not apply to claims arising under the Exchange Act or for any other federal securities laws which provide for exclusive federal jurisdiction